[Form 4] Evommune, Inc. Insider Trading Activity

Evommune, Inc. reported that Chief Medical Officer Eugene Bauer received an award of employee stock options covering 51,117 shares of common stock.

Rhea-AI Filing Summary

Evommune, Inc. reported that Chief Medical Officer Eugene Bauer received an award of employee stock options covering 51,117 shares of common stock. The options have an exercise price of $26.77 per share and expire on April 15, 2036.

One quarter of the options vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, contingent on his continued service. Following this grant, Bauer holds 51,117 derivative securities directly.

Insider Trade Summary

Grant/Award: 51,117 shares

Grant/Award 1 txn

Insider Bauer Eugene

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	51,117	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 51,117 contracts (Direct)

Footnotes (1)

1. F1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evommune (EVMN) report for Eugene Bauer?

Evommune reported that Chief Medical Officer Eugene Bauer received a grant of 51,117 employee stock options. These options give him the right to buy common shares at a fixed price, functioning as stock-based compensation rather than an open-market share purchase.

How many Evommune (EVMN) stock options were granted to the CMO?

Eugene Bauer was granted 51,117 employee stock options. Each option is tied to one share of Evommune common stock, providing potential future ownership if the options are exercised at or above the fixed exercise price.

What is the exercise price and expiration date of the Evommune options?

The granted options have a $26.77 per share exercise price and expire on April 15, 2036. Bauer can choose to exercise during this term once portions of the grant vest, subject to the continued service conditions described in the award.

How do the Evommune (EVMN) stock options granted to Bauer vest?

One fourth of the options vest on the first anniversary of the grant date, with the rest vesting in 36 equal monthly installments. Vesting depends on Bauer’s continuous service with Evommune through each vesting date under the award terms.

Is the Evommune Form 4 a stock purchase or compensation grant?

The Form 4 reflects a compensation-related stock option grant, not an open-market share purchase. Bauer received 51,117 options at no cost, allowing future purchases at $26.77 per share if he meets the vesting and service conditions.

How many Evommune derivative securities does Bauer hold after this grant?

After the reported grant, Bauer holds 51,117 derivative securities in the form of employee stock options. These options represent the right to acquire Evommune common shares in the future, subject to vesting and exercise decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/17/2026 - 05:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Eugene

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$26.77	04/16/2026		A		51,117		(1)	04/15/2036	Common Stock	51,117	$0.00	51,117	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)